flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Preventing chronic kidney disease and

By this point, many people have reached or are approaching the 8 mg to 12 mg dose range where the clinical data shows the most dramatic results

This difference influences treatment selection based on the severity of concerns and desired outcomes

Oral semaglutide, tirzepatide injections, and combination formulas are also available

(PubMed) Cantor AG, Bougatsos C, Dana T, Blazina I, McDonagh M

Cardiovascular Health: Semaglutide extends beyond blood sugar control, offering potential cardiovascular benefits and reducing associated risks

This includes but is not limited to, conducting checkups and asking questions over the phone and video chat options, handling simple advisory medical tasks over virtual platforms, and even administering medical care via services that can meet you at home or direct you to nearby resources